Loss of Dopamine Uptake Sites Labeled with [3H]GBR-12935 in Alzheimer’s Disease

Autor:	Kristina Eriksson, Arvid Carlsson, Jan Marcusson, Per Allard, Ewa Ericson, I. Alafuzoff, Carl-Gerhard Gottfries
Rok vydání:	1990
Předmět:	Pathology medicine.medical_specialty Chemistry Putamen Homovanillic acid GBR-12935 medicine.disease chemistry.chemical_compound Endocrinology Neurology Dopamine Internal medicine medicine Dementia Neurology (clinical) Alzheimer's disease Vascular dementia Neurotransmitter medicine.drug
Zdroj:	European Neurology. 30:181-185
ISSN:	1421-9913 0014-3022
DOI:	10.1159/000117341
Popis:	The binding of the dopamine uptake inhibitor [3H]GBR-12935 to postmortem putamen from a control group and patients with Alzheimer's disease/senile dementia of Alzheimer type (AD/SDAT) or vascular dementia (VD) was studied. The binding density (Bmax) in AD/SDAT was significantly reduced to 50% of control. A reduction of Bmax in VD was also noted, but it did not reach statistical significance. No differences in apparent binding affinity (Kd) between controls and dementia groups were obtained. The concentrations of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine (3-MT) and homovanillic acid were also determined. The concentrations of DA and DOPAC were reduced by 30-40% in AD/SDAT and VD, but the reductions did not reach statistical significance. The concentration of 3-MT was reduced by 40% in AD/SDAT and by 30% in VD. The [3H]GBR-12935-binding densities correlated significantly with corresponding concentrations of DA in control brains. It is suggested that the loss of [3H]GBR-12935-binding sites in human putamen in AD/SDAT reflects a degeneration of dopamine neurites.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::776a713657fffbb7c3e1f8f521c9169d https://doi.org/10.1159/000117341 Zobrazit plný text záznamu